

## McKesson Corporation (MCK)

**\$155.79** (As of 08/17/20)

Price Target (6-12 Months): **\$164.00**

Long Term: 6-12 Months

**Zacks Recommendation:**

**Neutral**

(Since: 11/24/19)

Prior Recommendation: Outperform

Short Term: 1-3 Months

**Zacks Rank:** (1-5)

**3-Hold**

Zacks Style Scores:

VGM:B

Value: A

Growth: C

Momentum: C

### Summary

McKesson exited the fiscal first quarter on a strong note. Strong fiscal first-quarter show by U.S. Pharmaceutical and Specialty Solutions is a positive. The company continues to remain optimistic about the McKesson and Walgreens Boots Alliance agreement to form a joint venture that is anticipated to combine their respective pharmaceutical wholesale businesses in Germany. Strong fiscal 2021 outlook also buoys optimism. The company outperformed the industry in a year's time. Meanwhile, the company witnessed weak performance across European Pharmaceutical Solutions, Medical-Surgical Solutions and Other segments in the quarter under review. Further, contraction in gross margin adds to woes. Price fluctuation of generic pharmaceuticals and stiff competition in the MedTech space remain concerns.


### Price, Consensus & Surprise



### Data Overview

52 Week High-Low	\$172.18 - \$112.60
20 Day Average Volume (sh)	1,099,503
Market Cap	\$25.3 B
YTD Price Change	12.6%
Beta	0.82
Dividend / Div Yld	\$1.68 / 1.1%
Industry	<a href="#">Medical - Dental Supplies</a>
Zacks Industry Rank	Top 30% (75 out of 252)

### Sales and EPS Growth Rates (Y/Y %)



Last EPS Surprise	17.9%
Last Sales Surprise	3.0%
EPS F1 Est- 4 week change	5.3%
Expected Report Date	11/04/2020
Earnings ESP	0.0%
P/E TTM	10.8
P/E F1	10.3
PEG F1	1.5
P/S TTM	0.1

### Sales Estimates (millions of \$)

	Q1	Q2	Q3	Q4	Annual*
2022	60,000 E	61,960 E	64,496 E	63,388 E	251,614 E
2021	55,679 A	59,317 E	62,566 E	61,506 E	238,934 E
2020	55,728 A	57,616 A	59,172 A	58,535 A	231,051 A

### EPS Estimates

	Q1	Q2	Q3	Q4	Annual*
2022	\$3.74 E	\$3.99 E	\$4.26 E	\$4.87 E	\$16.90 E
2021	\$2.77 A	\$3.83 E	\$4.00 E	\$4.55 E	\$15.13 E
2020	\$3.31 A	\$3.60 A	\$3.81 A	\$4.27 A	\$14.95 A

\*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 08/17/2020. The reports text is as of 08/18/2020.

## Overview

San Francisco, CA-based McKesson Corporation is a health care services and information technology company. McKesson operates through two segments:

The Distribution Solutions segment distributes branded and generic pharmaceutical drugs along with other healthcare-related products on a global basis worldwide. The segment also provides practice management, technology, clinical support and business solutions to community-based oncology and other specialty practices. In addition, the segment provides specialty pharmaceutical solutions for pharmaceutical manufacturers including offering multiple distribution channels and study access to oncology physicians. The segment also provides medical-surgical supply distribution, equipment, logistics and other services to healthcare providers within the U.S.

The Technology Solutions segment provides enterprise-wide clinical, patient care, financial, supply chain, and strategic management software solutions.


However, in the first quarter of fiscal 2019, McKesson reported revenues through three segments: U.S. Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions, Medical-Surgical Solutions.

### Acquisitions

In Jan 2018, McKesson announced that it has completed the acquisition of RxCrossroads from CVS Health Corp. RxCrossroads is a provider of tailored services to pharmaceutical and biotechnology manufacturers. The transaction is valued at \$735 million and has been entirely funded by cash on hand. RxCrossroads will become part of McKesson's Specialty Health business. In Jun 2018, McKesson completed the acquisition of MSD for the net purchase consideration of \$784 million, which was funded from cash on hand.

### FY20 at a Glance

Revenues in fiscal 2020 grossed \$231.05 billion, compared with \$214.31 billion a year ago. U.S. Pharmaceutical and Specialty Solutions (79% of net revenues), European Pharmaceutical Solutions (12%), Medical-Surgical Solutions (4%) and Other (4%).



## Reasons To Buy:

▲ **Share Price Performance:** In the past year, shares of McKesson have gained 6.7% against the industry's decline of 2.2%. Multi-year growth initiatives, acquisitions and strategic collaborations, and strong position in the pharmaceutical and medical supplies distribution market buoy the company's prospects.

▲ **Multi-Year Growth Initiatives:** In recent times, McKesson announced a multi-year strategic growth initiative, focused on creating innovative new solutions that improve patient care delivery and drive incremental profit growth. The plan is to implement differential pricing for brand, generic, specialty, biosimilar and OTC (Over-the-counter) drug classes in line with services offered to both customers and manufacturers. As discussed in the fiscal first-quarter 2021 earnings call, McKesson continues to remain focused when it comes to its multi-year strategic growth initiative update that is currently expected to generate approximately \$400 million to \$500 million in annual pre-tax gross savings. This will be substantially realized by the end of fiscal 2021.

Management aims to increase efficiency, accelerate execution and improve long-term performance through its initiatives that consist of multiple growth pillars.

▲ **Strong Player in Distribution Market:** McKesson is a major player in the pharmaceutical and medical supplies distribution market.

The Distribution Solutions segment caters to a wide range of customers and businesses and stands to benefit from increased generic utilization, inflation in generics driven by several patent expirations in the next few years, and an aging population.

It is encouraging to note that, in the fiscal fourth quarter 2019, Rite Aid renewed its 10-year distribution and sourcing relationship with McKesson, while pharmaceutical distribution relationship with CVS Health was renewed through June 2023.

Additionally, in the fiscal third quarter 2019, McKesson launched its Opioid Foundation that will focus on helping advance solutions to the U.S. opioid crisis. Per management, the company has contributed \$100 million toward building the foundation for opioid response efforts — a foundation dedicated entirely for driving solutions to the epidemic.

▲ **Acquisitions & Strategic Collaborations:** McKesson has been actively pursuing deals, divestitures and acquisitions to drive growth. Recently, MedTech bigwig, Cerner Corporation collaborated with McKesson's CoverMyMeds, a wholly-owned subsidiary of its Prescription Technology Solutions sub unit.

In recent past, McKesson completed the acquisition of RxCrossroads from CVS Health Corp. RxCrossroads is a provider of tailored services to pharmaceutical and biotechnology manufacturers. The transaction is valued at \$735 million and has been entirely funded by cash on hand. McKesson had also acquired electronic prior authorization solutions provider to pharmacies, providers, payers and pharmaceutical manufacturers—CoverMyMeds.

During the fiscal third quarter, CoverMyMeds and RxCrossroads announced the launch of AMP (Access for More Patients), which is a first-in-class technology driven patient support solution that transforms how patients access afford and adhere to their medications.

On Dec 12, 2019, McKesson and Walgreens Boots Alliance announced an agreement to form a joint venture (JV) that is anticipated to combine their respective pharmaceutical wholesale businesses in Germany.

▲ **Divestitures:** In an initiative to focus on core strength, McKesson's divested Enterprise Information segment in recent past. Notably, the Enterprise Information Solutions portfolio included a robust set of clinical and financial solutions supporting the full scope of care delivery processes — including Paragon (EHR solution); STAR and HealthQuest (Revenue Cycle solutions); Lab Analytics and Blood Bank; and OneContent (Content Management solutions).

Notably, on February 4, 2020, McKesson's wholly-owned subsidiary, PF2 SpinCo, Inc., filed a registration statement with the Securities and Exchange Commission (SEC) with regards to a potential exit of the company from its investment in the Change Healthcare JV.

Separating Technology Business: In recent past, McKesson divested its Technology Solutions business and merged the same with Change Healthcare Holdings to form a new healthcare information technology entity.

The Technology Solutions business had been facing challenges for quite some time as revenues declined. Hence, in a bid to focus on its core distribution business, McKesson offered the majority of its Technology Solutions businesses to Change Healthcare but has retained RelayHealth Pharmacy and Enterprise Information Solutions (EIS). McKesson is currently holding 70% of the new company. Meanwhile, McKesson's Prescription Technology Solutions displayed strong performance in the fiscal first quarter. Per management, the company continues to make investments in this business, which in turn will position it well for future growth.

On Mar 10, 2020, McKesson completed the separation of its investment in Change Healthcare.

▲ **McKesson Canada Improves:** McKesson Canada plays a crucial role in providing solutions to manufacturers, pharmacies and hospitals, which cater to the needs of patients in Canada every day.

Additionally, McKesson Canada also has broad specialty assets and capabilities. The company is also well-positioned to participate in the growth of specialty in the Canadian market. In Canada, the company's retail pharmacies have remained open, thereby offering the essential community-based care that its customers bank upon. Moreover, the company is expanding its pharmacy services to include virtual health offerings, home delivery in certain markets, and increased online pharmacy capabilities.

▲ **Stable Liquidity Position:** McKesson exited fiscal first quarter with cash and cash equivalents of \$2.61 billion, down from \$4.01 billion sequentially. The company's long-term debt came in at \$8.02 billion in the quarter under review, which increased from \$7.99 billion on a

McKesson has been pursuing deals and acquisitions to drive growth. The company is a major player in the pharmaceutical and medical supplies distribution market.

---

sequential basis. Although, the quarter's long-term debt is much higher than the corresponding cash and cash equivalent level, the current-year debt is at \$1.41 billion, which remained flat on a sequential basis, is noticeably lower than the short-term cash level. This is good news in terms of the company's solvency level as, at least during the year of economic downturn, the company is holding sufficient cash for debt repayment.

McKesson's capital deployment policy is based on the return of shareholders' money through share repurchases and dividends. The company returned \$74 million to its shareholders in the form of dividends in the fiscal first quarter, while having \$1.5 billion remaining in its share repurchase authorization. Further, the current payout ratio is at a low level of 11.3%, indicating sustainability of its current dividend payment.

---

---

## Reasons To Sell:

▼ **Other Global Headwinds:** Management stated in fiscal first-quarter 2021 earnings call stated that adjusted operating profit is anticipated to decrease in the range of 1-4% for fiscal 2021. With respect to US Pharmaceutical and Specialty solutions, the company expects adjusted segment operating profit in the range of (2%)-2% for the full-year fiscal 2021. Further, revenues in the European Pharmaceutical Solutions are anticipated in the range of (3%) to 1% in 2021 compared with the previous year. Adjusted operating is also estimated to fall in the range of 4-9%.

For the remaining businesses included in Other, revenues are estimated to decrease around 5-10% owing to anticipated lower foot traffic in retail stores across Canada in the short-term and lower prior authorization volumes.

With respect to the company's corporate segment, opioid-related costs is anticipated to be around \$160 million for fiscal 2021. Given the higher opioid-related costs and increased investment in the business, the company now estimates corporate expenses between \$690 million and \$740 million.

▼ **Weak Trends:** McKesson distributes generic pharmaceuticals, which are subject to price fluctuation. The Distribution Solutions segment had experienced weaker generic pharmaceutical pricing trends, which continue to persist. Continued volatility, unfavorable pricing trends, reimbursement of generic drugs, significant fluctuations in the nature, frequency and magnitude of generic pharmaceutical launches could have a material adverse impact on McKesson.

▼ **Stiff Competition:** Distribution Solutions faces stiff competition both in terms of price and service from various full-line, short-line and specialty wholesalers, service merchandisers, self-warehousing chains, manufacturers engaged in direct distribution, third-party logistics companies and large-payer organizations. Moreover, the company depends on fewer suppliers for its products. As a result, it is not in a position to negotiate pricing.

Also, the prices for company's products and services may erode due to greater bargaining power of other healthcare enterprises. In addition, the company's Technology Solutions segment experiences substantial competition from many firms, including other software services firms, consulting firms, shared service vendors, certain hospitals and hospital groups, payers, care management organizations, hardware vendors and internet-based companies with technology applicable to the healthcare industry.

---

Sluggish growth in the pharmaceutical distribution business is concerning. Global regulatory headwinds persist.

## Last Earnings Report

### McKesson Q1 Earnings and Revenues Surpass Estimates

McKesson Corporation reported first-quarter fiscal 2021 adjusted earnings per share of \$2.77, which beat the Zacks Consensus Estimate of \$2.35 per share by 17.9%. However, the bottom line declined 16.3% on a year-over-year basis.

Revenues of \$55.68 billion outpaced the Zacks Consensus Estimate by 3%. However, the figure fell 0.1% year over year.

Quarter Ending **06/2020**

Report Date	Aug 03, 2020
Sales Surprise	<b>3.02%</b>
EPS Surprise	<b>17.87%</b>
Quarterly EPS	<b>2.77</b>
Annual EPS (TTM)	<b>14.45</b>

### Q1 Segmental Analysis

Revenues at the **U.S. Pharmaceutical and Specialty Solutions** segment were \$45.06 billion, up 2% year over year. Per management, the upside was primarily driven by market growth and increase in volumes from retail national account customers. However, branded to generic conversions partially offset the upside.

At the **European Pharmaceutical Solutions** segment, revenues amounted to \$6.25 billion, down 6.9% year over year. Further, the metric decreased 4% at constant currency (cc) owing to lower volumes in the pharmaceutical distribution business.

Revenues at the **Medical-Surgical Solutions** segment totaled \$1.80 billion, down 5.4% year over year. Decline in the Primary Care business, owing to lower primary care patient visits, was the primary factor behind the downside. However, higher volumes of personal protective equipment (PPE) partially mitigated the downside.

Revenues at the **Other** segment were \$2.57 billion in the fiscal first quarter, declining 12.9% year over year and 10% at cc. Lower pharmaceutical volumes in the Canadian business led to the decline.

### Margins

Gross profit in the reported quarter was \$2.70 billion, down 3.1% on a year-over-year basis. Meanwhile, gross margin was 4.8% of net revenues, down 20 bps.

Operating income in the quarter was \$678 million, up 6.9% from the year-ago quarter.

The U.S. Pharmaceutical and Specialty Solutions segment reported adjusted operating profit of \$589 million, down 2% from the prior-year quarter. Adjusted operating margin was 1.3% at the segment.

Adjusted operating profit at the European Pharmaceutical Solutions segment was \$36 million, up 3% from the year-ago quarter. Meanwhile, the adjusted operating margin at the segment was 0.6%.

The Medical-Surgical segment had adjusted operating profit of \$124 million, which declined 22% from the year-ago quarter. Adjusted operating margin was 6.9% at the segment.

Adjusted operating profit was \$137 million at the Other segment, down 50% from the prior-year quarter.

### Financial Update

In the quarter under review, cash and cash equivalents were \$2.61 billion, down 34.9% sequentially.

Cumulative cash used in operating activities for the fiscal first quarter amounted to \$1.06 billion, significantly up from \$51 million of cash used in operating activities in the year-ago period.

### Fiscal 2021 Guidance Raised

For fiscal 2021, McKesson projects adjusted earnings per share in the range of \$14.70-\$15.50 (up from the previously guided range of \$13.95-\$14.75). The Zacks Consensus Estimate for the same is pegged at \$15.10.

The company anticipates adjusted earnings per share growth in the second half of fiscal 2021.

## Recent News

### McKesson Extends Partnership to Fight the COVID-19 Pandemic: Aug 14, 2020

McKesson Corporation recently announced that it will extend its existing partnership with the Centers for Disease Control (CDC) to help the U.S. government's Operation Warp Speed (OWS) team. With this collaboration, McKesson will become the centralized distributor of future COVID-19 vaccines and ancillary supplies required to administer vaccinations.

## Valuation

McKesson's shares are up 12.6% and 6.7% in the year-to-date period and the trailing 12-month periods, respectively. Stocks in the Zacks sub-industry and Zacks Medical Market are up 6.5% and 0.4% in the year-to-date period, respectively. Over the past year, the stocks in the Zacks sub-industry are down 2.3% while that in the sector are up 7.6%.

The S&P 500 index is up 4.5% in the year-to-date period and 15.4% in the past year.

The stock is currently trading at 9.9X Forward 12-months earnings, which compares to 18.9X for the Zacks sub-industry, 22.2X for the Zacks sector and 22.9X for the S&P 500 index.

Over the past five years, the stock has traded as high as 16.1X and as low as 7.31X, with a 5-year median of 11.1X.

Our Neutral recommendation indicates that the stock will perform in line with the market. Our \$164 price target reflects 10.4X forward 12-months earnings.

The table below shows summary valuation data for MCK.

Valuation Multiples - MCK					
		Stock	Sub-Industry	Sector	S&P 500
P/E F12M	Current	9.85	18.99	22.16	22.85
	5-Year High	16.08	19.84	23.17	22.85
	5-Year Low	7.31	13.63	15.89	15.25
	5-Year Median	11.08	16.47	18.97	17.58
P/S F12M	Current	0.1	0.37	2.8	3.7
	5-Year High	0.25	0.38	3.41	3.7
	5-Year Low	0.09	0.23	2.22	2.53
	5-Year Median	0.14	0.28	2.89	3.05
P/B TTM	Current	4.47	3.54	3.76	4.52
	5-Year High	5.6	4.73	5.07	4.56
	5-Year Low	2.22	2.54	2.94	2.83
	5-Year Median	3.31	3.44	4.28	3.74

As of 08/17/2020

## Industry Analysis Zacks Industry Rank: Top 30% (75 out of 252)



## Top Peers

Company (Ticker)	Rec	Rank
Patterson Companies, Inc. (PDCO)	Outperform	2
AmerisourceBergen Corporation (ABC)	Neutral	3
Becton, Dickinson and Company (BDX)	Neutral	3
Cardinal Health, Inc. (CAH)	Neutral	3
Henry Schein, Inc. (HSIC)	Neutral	3
Laboratory Corporation of America Holdings (LH)	Neutral	3
DENTSPLY SIRONA Inc. (XRAY)	Neutral	3
The Cooper Companies, Inc. (COO)	Underperform	4

Industry Comparison Industry: Medical - Dental Supplies				Industry Peers		
	MCK	X Industry	S&P 500	ABC	BDX	CAH
Zacks Recommendation (Long Term)	Neutral	-	-	Neutral	Neutral	Neutral
Zacks Rank (Short Term)	3	-	-	3	3	3
VGM Score	B	-	-	A	C	B
Market Cap	25.27 B	2.46 B	23.75 B	21.11 B	75.38 B	15.42 B
# of Analysts	9	5	14	7	12	7
Dividend Yield	1.05%	0.00%	1.62%	1.62%	1.22%	3.69%
Value Score	A	-	-	A	C	B
Cash/Price	0.10	0.06	0.07	0.16	0.04	0.18
EV/EBITDA	12.50	14.81	13.49	13.14	22.00	-7.41
PEG Ratio	1.48	3.19	3.03	1.76	3.19	1.94
Price/Book (P/B)	4.47	4.69	3.18	5.32	3.14	8.59
Price/Cash Flow (P/CF)	7.30	15.95	12.85	10.69	12.52	6.11
P/E (F1)	10.37	36.71	22.17	13.15	26.05	9.73
Price/Sales (P/S)	0.11	2.75	2.49	0.11	4.46	0.10
Earnings Yield	9.71%	2.33%	4.32%	7.61%	3.84%	10.28%
Debt/Equity	1.42	0.44	0.77	0.91	0.71	3.78
Cash Flow (\$/share)	21.35	1.35	6.94	9.67	20.77	8.62
Growth Score	C	-	-	B	B	B
Hist. EPS Growth (3-5 yrs)	4.38%	9.48%	10.44%	8.81%	10.16%	1.54%
Proj. EPS Growth (F1/F0)	1.20%	-3.80%	-5.97%	10.96%	-14.53%	-0.52%
Curr. Cash Flow Growth	-33.76%	3.87%	5.22%	-0.05%	14.64%	-2.74%
Hist. Cash Flow Growth (3-5 yrs)	-0.50%	12.37%	8.52%	12.37%	24.86%	5.57%
Current Ratio	1.00	1.53	1.33	0.98	1.45	1.10
Debt/Capital	62.54%	32.99%	44.59%	47.71%	41.57%	79.06%
Net Margin	0.40%	0.23%	10.13%	0.84%	5.30%	-2.42%
Return on Equity	42.33%	11.36%	14.51%	46.04%	14.19%	130.94%
Sales/Assets	3.87	0.90	0.51	4.60	0.32	3.77
Proj. Sales Growth (F1/F0)	3.41%	0.00%	-1.67%	5.00%	-2.67%	4.25%
Momentum Score	C	-	-	B	F	F
Daily Price Chg	-1.82%	0.00%	-0.02%	-0.32%	0.72%	-1.77%
1 Week Price Chg	4.39%	-0.02%	1.09%	1.62%	0.69%	2.09%
4 Week Price Chg	1.49%	0.00%	4.83%	1.20%	-2.92%	-0.79%
12 Week Price Chg	4.26%	6.12%	13.09%	11.04%	8.69%	-1.60%
52 Week Price Chg	6.73%	11.35%	2.77%	17.86%	3.40%	21.27%
20 Day Average Volume	1,099,503	515,521	1,932,479	788,618	1,273,283	2,352,238
(F1) EPS Est 1 week change	0.00%	0.00%	0.00%	0.01%	0.00%	-0.65%
(F1) EPS Est 4 week change	5.33%	2.34%	1.80%	6.23%	-4.31%	1.91%
(F1) EPS Est 12 week change	-0.64%	0.35%	2.88%	5.55%	-5.41%	1.34%
(Q1) EPS Est Mthly Chg	22.66%	0.00%	0.80%	11.11%	-16.11%	-1.47%



---

## Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

### Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we have an excellent balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

### Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

---

### Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

Value Score	A
Growth Score	C
Momentum Score	C
VGM Score	B

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

---

### Disclosures

**This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page.** Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.